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High risk factors in transplantation
Luis H Toledo -Pereyra
SUMMARY
A standardised system ofassessing riskfactors forrenal transplant outcome and
patient survival has been assessed.
INTRODUCTION
The growth of renal transplantation in the past decade and the increased amount
of clinical experience in this area has allowed many transplant centres to broaden
their criteria for patient selection. This has resulted in the acceptance of many
patients, who were formerly considered as being 'non-ideal', into renal transplant
programmes. While individual risk factors such as diabetes mellitus, cardio-
vascular disease, hypertension, age and race have been pointed out,1 9 no
standardised system has been employed to evaluate the contributions of the
various risk factors to renal transplant outcome and patient survival.
At our centre, we have considered the combined effects of the multiple risk
factors that are often simultaneously present in these patients prior to trans-
plantation.10 This has led to development of a scale for comparison of individual
risk factors (Table 1). Cumulative risk is then determined for each patient and
transplant candidates are placed in an overall risk category. This allows for a more
realistic pre-transplant evaluation. The present study compares the post-
transplantation outcomes of two groups of high-risk renal allograft recipients at
our centre receiving different immunosuppressive regimens.
PATIENT POPULATION AND IMMUNOSUPPRESSION
Group I ofthe study comprised 100 consecutive kidney transplants performed in
89 patients from September 1979 to November 1981. Follow-up of these
patients was up to three years post-transplant. Eighty patients received primary
renal transplants and 14 were transplanted with second renal allografts from
cadaver donors. The remaining 6 patients received renal grafts from living related
donors. Immunosuppression for patients in Group I consisted of azathioprine,
prednisolone and antilymphoblast globulin (ALG). Rejection episodes were
treated with ALG without increasing steroids.11 12
The thirty patients in Group 11 were transplanted at our centre between December
1983 and August 1984. Twenty patients received primary kidney allografts, 6
patients received second renal transplants and 2 patients received a third renal
graft from cadaver donors. Two patients were transplanted with kidneys from
living related donors. Immunosuppression for these patients consisted of
cyclosporin and prednisolone. Cyclosporin A was given pre-operatively at a
dosage of 4-5 mg/kg (intravenously). No cyclosporin A was given during the
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TABLE I
Grading system forindividual determinants contributing to cumulative risk to life
ofrenal transplant recipients
RiskFactor R.R.I. *
Severe cardiac disease 0.50
Severe pulmonary disease 0.50
Disseminated collagen disease 0.50
Insulin dependent diabetes mellitus 0.40
Severe malnutrition (.<50% ideal bodyweight) 0.40
Severe obesity ( .60% ideal bodyweight) 0.40
Severe hypertension (diastolic pressure >1 10) 0.40
Oxalosis 0.40
Fabry's disease 0.40
Re-transplantation 0.40
Severe bladder disease (diversion required) 0.30
Drug addiction 0.30
Age .45 years 0.30
Liver disease 0.30
Peptic ulcer 0.30
Pancreatic disease 0.30
Controlled systemic infections 0.25
Majorpsychiatric disturbances 0.25
Diverticulosis 0.25
Amyloidosis 0.25
Rapid progressive glomerulonephritis 0.20
Pre-existing controlled malignancy 0.20
High level cytotoxic antibodies ( >60%) 0.20
No blood transfusions 0.20
Persistent alcoholism 0.20
Membranoproliferative glomerulonephritis 0.20
Goodpasture's syndrome 0.20
Other recurrentglomerulonephritis 0.20
Focal glomerulosclerosis 0.10
Peptic ulcerdisease 0.10
Heavy smoking 0.10
Endocrinopathy 0.10
Sickle cell anaemia 0.10
Hepatitishistory 0.10
Poorantigen matching ( .2 antigen match) 0.10
*Relative Risk Index.
first 24 hours after transplantation, an oral dose of 4-5 mg/kg was administered
on post-operative days 1 -3, and 6-8 mg/kg on days 4- 5. The serum cyclo-
sporin A levels were determined on days 4 and 5, and the dose was then adjusted
to maintain serum levels between 100 and 200 mg/ml. After two months the
dose was fixed at 4-5 mg/kg daily regardless of serum levels. Prednisolone
1 mg/kg was given immediately prior to transplant. No prednisolone was given
during the first 24 hours post-operatively. Patients received prednisolone at a
© The Ulster Medical Society, 1985.
S77The Ulster Medical Journal
dosage of 1 mg/kg on day 2, 0.75 mg/kg on days 3-5, 0.5 mg/kg on days
5 -7, and were maintained at this level until discharge. Within two weeks post-
transplantation, prednisolone was tapered to 20 mg daily and decreased to
5-7.5 mg daily within 3 months after transplant. Some patients were later
completely removed from prednisolone. Rejection was treated with methyl-
prednisolone sodium succinate, 250 mg administered intravenously every 8- 12
hours for 3 days. Occasionally, antilymphocytic globulin was used to treat
rejection when no response to methylprednisolone was obtained.
ANALYSIS OF RISK
Each patient in Groups I and 11 was evaluated to determine his or her cumulative
risk prior to transplantation. Each individual risk factor was weighted as in Table I
and a final risk index was calculated by adding these together. Patients with a risk
index < .6 were considered to be good risk candidates for transplantation. Risk
indices .6 < x < .9 were considered to be at high risk. The very high risk
category included cumulative indices in the .9 < x < 1.1 range. Extremely high
risk was indicated by indices > 1.1.
RESULTS
Table II compared the 6 months actuarial patient survival for each risk category in
each of the groups. Survival was observed to decrease as the cumulative risk to
life increased in the antilymphocytic globulin treated group. Only one death from
sepsis occurred in an extremely high risk recipient in the cyclosporin A group.
When age was a risk factor, other risk factors were also frequently associated,
such as severe cardiac disease, hypertension, obesity or malnutrition.
TABLE II
Effect of risk on patient survival in antilymphocytic globulin or cyclosporin A
immunosuppressed patients
Six Month Actuarial Patient Survival
Group I Group 11
Risk Category (antilymphocytic (cyclosporinA) p
globulin)
N % N %
Good risk 37 100 10 100 NS
High risk 27 88.5 7 100 p<0.1
Very high risk 15 78.1 9 100 p<0.01
Extremely high risk 21 71.0 4 75 NS
Statistical comparison using Chi-square method.
DISCUSSION
Many authors have considered the effects of individual risk factors, present
before transplantation, on the post-operative outcome. These determinants
include age,2 13.16 preformed cytotoxic antibodies,5 re-transplantation,5 blood
transfusion,"56 15 Fabry's disease,17 18 race,7,9 15 malignant hypertension,7
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glomerulonephritis,7 16 HLA-A, -B matching'4 and diabetes mellitus.14 The
preliminary analysis of risk factors in ourtransplant population has included these
determinants as well as others in an effort to evaluate the cumulative effects of
risk factors in renal transplantation.'0 This initial assessment categorised risk
factors and assigned relative risk indices to each. When we applied this system to
our transplant population, we found that, even though we did not employ a
complex statistical analysis, our system was valid for grouping patients into risk
categories as part of their pre-transplant evaluation. A relationship was observed
between antilymphocytic globulin immunosuppressed patients in good, high,
very high, or extremely high risk categories, and prognosis after transplantation.
It is apparent that a well developed system for determining the risk to life as part
of the pre-transplant evaluation would be useful for decision-making both before
and after transplantation. Accurate determinations of this risk could be used to
individualise immunosuppressive therapy and would assist decisions regarding
pursuit of re-transplantation after a graft has been lost to rejection. The results
obtained from application of our risk categorisation system to cyclosporin A
treated renal transplant recipients was affected by an overall reduction in patient
mortality as compared with the previous antilymphocytic globulin treated group.
Although our patient populations are small in both groups, this improvement in
survival may be due to the steroid-sparing effect ofcyclosporin A administration.
Major risk factors such as cardiac disease and hypertension will cause fatal
complications late in the course of the transplants, which will further influence
survival.
We encourage other centres to utilise our system for risk categorisation or to
modify it to accommodate the risk factors which may be additionally present in
their patient population. In this way, risk categorisation may become an integral
part of the pre-transplant patient evaluation and can be used to predict outcome
after renal transplantation.
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